Core Viewpoint - C百奥 (688796) experienced a significant increase of 146.63% on its first trading day, with a turnover rate of 75.80% and a transaction volume of 1.671 billion yuan [2]. Company Overview - C百奥 specializes in gene editing technology, providing innovative model animals and preclinical pharmaceutical research services. The company utilizes its proprietary RenMice platform for large-scale drug discovery targeting over a thousand potential drug targets in humans [2]. - The company has developed into an enterprise with four technical platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [2]. Financial Performance - On its first trading day, C百奥 had a financing buy-in amount of 123 million yuan, accounting for 7.39% of the total trading volume, with a latest financing balance of 111 million yuan, representing 4.72% of the circulating market value [2]. - The stock attracted a net inflow of 765 million yuan from major funds, with large single orders contributing 428 million yuan and big orders contributing 337 million yuan [2].
C百奥上市首日融资余额1.11亿元